1 active not recruiting, 1 completed, 1 terminated. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
Follow Piperacillin: new trials by email Literature Review of Piperacillin trials Research Report on Piperacillin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison Between Carbapenems and Noncarbapenem Beta-lactam Antibiotics in Septic Burn Patients Meropenem I.V. 2g as a 3 hour infusion every 8 hours, Tazocin (pipercillin/tazobactam) - Sepsis | Phase 1 / Phase 2 | Active not recruiting | Ain Shams University | 400 | 2024-01-01 | 2025-10-03 |
| A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%, piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%, piperacillin 2% + tazobactam 0.25% - Otitis Media, Otorrhea | Phase 1 / Phase 2 | Terminated | Yuhan Corporation | 135 | 2016-06-01 | 2022-01-13 |
| Study Evaluating BLI-489 and Piperacillin in Healthy Subjects BLI-489/Piperacillin, BLI-489, Piperacillin - Healthy Subjects | Phase 1 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 24 | 2009-05-01 | 2009-07-17 |
Burns (1) · Otitis Media (1) · Sepsis (1)
Ain Shams University (1) · Wyeth is now a wholly owned subsidiary of Pfizer (1) · Yuhan Corporation (1)
Egypt (1) · South Korea (1) · United States (1)
Aya A Bayoumy, MD (1) · Mohamed A Ali, MD (1) · Osama R Abdelmalek, MD (1) · Thabet A Botros, MD (1)